ArticleClinical parkinsonism & related disorders2025
Expectations regarding regenerative medicine and attitudes toward invasive surgical therapies in patients with Parkinson's disease: A cross-sectional survey.
Article in Clinical parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pharmacological control of the motor symptoms of Parkinson's disease (PD) is challenging with disease progression. Device-aided therapies help relieve these symptoms but are invasive and require specific management. Induced pluripotent stem (iPS) cells avoid ethical concerns and may prevent immune rejection in autologous transplants. Allogeneic iPS cells are considerably more practical, despite potential concerns regarding tumor formation post-transplantation. The present study aimed to clarify the perceptions and acceptance of patients with PD regarding regenerative medicine, invasive surgical treatments (deep brain stimulation, levodopa-carbidopa intestinal gel), and cell transplantation (iPS cells, embryonic stem cells, fetal-derived cells). Methods: This prospective cross-sectional survey of 102 patients with PD applied a new questionnaire based on a previous survey of the general public's perception of regenerative medicine. Results: Cell-based therapies were the most popular choice, with 86.1 % of responders choosing it, mainly due to "improvement in quality of life" (69.1 %), "the possibility of slowing the disease progression" (66.2 %), and "treatment effectiveness" (51.5 %). Among these patients, 47.1 % expected regenerative medicine to become the standard therapy within several years and 82.4 % believed that regenerative medicine was safe. Autologous iPS cells were accepted by 83.8 % of the patients, while 52.5 % accepted allogeneic iPS cells. Conclusions: Patients had high expectations for the therapeutic effects of cell-based therapies and were optimistic about its early implementation and safety in regenerative medicine, with iPS cells being the most accepted for transplantation. The present findings should be confirmed in a larger cohort, as these findings are based on a limited sample.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.